Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: New evidence, implications and outstanding issues

Current Opinion in Lipidology

Volumn 7, Issue 6, 1996, Pages 341-355

  Watts, Gerald F ^a,b   Burke, Valerie ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CHOLESTEROL; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; ANGIOCARDIOGRAPHY; APHERESIS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFECT; ECHOGRAPHY; FEMALE; HEALTH ECONOMICS; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIMARY PREVENTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; SCREENING TEST; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030499842     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199612000-00002     Document Type: Review

References (108)

1. Oliver M, Poole-Wilson P, Shepherd J, Tikkanen MJ: Lower patients' cholesterol now. Trial evidence shows clear benefits from secondary prevention. BMJ 1995, 310:1280-1281.
2. Wood DA: Cholesterol lowering does have a role in secondary prevention. Br Heart J 1995, 73:4-5.
3. Swan HJC: Why cardiologists must be interested in lipids. Am J Cardiol 1995, 75:1067-1068.
4. LaRosa JC: Unresolved issues in early trials of cholesterol lowering. Am J Cardiol 1995, 76:5C-9C.
5. Jones PH: Trials of lipid-lowering therapy in primary prevention of coronary heart disease. Curr Opin Lipidol 1995, 6:365-368.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995, 333:1301-1307. Landmark study from the West of Scotland demonstrating reduction in incidence of MI and cardiovascular mortality in men with moderate hypercholesterolaemia and no CAD. Importantly there was no increase in mortality attributable to noncardiovascular causes.
7. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
8. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD: Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995, 91: 2274-2282. A novel meta-analysis of randomized trials over 2 years demonstrating that cholesterol lowering is beneficial, with the suggestion that fibrates may be responsible for an increase in non-coronary heart disease mortality and that hormones increase the risk of coronary heart disease.
9. Levine GN, Keaney JF, Vita JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Eng J Med 1995, 332:512-521. A useful review summarizing evidence for the relationship between hypercholesterolaemia and CAD, as well as data from clinical and regression studies with reference to underlying mechanisms.
10. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D: Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995, 92:3172-3177. This fundamental study showed that cholesterol reduction may decrease the risk of acute coronary events by decreasing platelet thrombus formation. Reduction in thrombogenicity may explain early reduction in clinical events after onset of therapy in pravastatin trials.
11. Feinstein AR: Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 1995, 48:71-79.
12. Vandenbroucke JP, Westerdorp RGJ: Are the effects of cholesterol lowering drugs always equal? Lancet 1996, 347:1267-1268.
13. Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park J-S, Salonen JT: Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995, 92:1758-1764. New ultrasonographic data from a primary prevention setting demonstrating that in hypercholesterolaemic men pravastatin decreases the rate of carotid atherosclerosis progression. The effect is mediated by LDL-cholesterol lowering and is greater in smokers than in non-smokers.
14. Salonen R, Nyyssönen K, Porkkala-Sarataho E, Salonen JT: The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995, 76:34C-39C. Additional data from the Kuopio Atherosclerosis Prevention Study showing that the antiatherogenic effect of pravastatin may, in part, be caused by increased resistance of LDL to oxidation.
15. Furberg CD, Adams Jr HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994, 90:1679-1687.
16. ••] showing that pravastatin decreases progression of intimal-medial thickness.
17. ••] based on ultrasonography showing that pravastatin has a antiatherogenic effect in peripheral arteries, but on a per patient basis this was not correlated with treatment effects in the coronary arteries.
18. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C-R, Liu C-H, Alaupovic P, Kwong-Fu H, Azen SP: Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. A randomized, controlled clinical trial. Ann Intern Med 1996, 124:548-556. Sub-study from the Monitored Atherosclerosis Regression Study [69] showing that cholesterol lowering with lovastatin reduces progression of early carotid atherosclerosis. Both cholesterol-rich and triglyceride-rich lipoproteins were positively correlated with progression of carotid atherosclerosis.
19. Genest Jr J, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson PWF, Salem DN, Schaefer EJ: Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992, 19:792-802.
20. Pfeffer MA, Sacks FM, Moyé LA, Brown L, Rouleau JL, Hartley LH, Rouleau J, Grimm R, Sestier F, Wickemeyer W, Cole TG, Braunwald E, for the CARE Investigators: Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. Am J Cardiol 1995, 76:98C-106C. Trial characteristics of the CARE study that addressed the issue of cholesterol lowering therapy in patients with CAD and serum cholesterol levels below 6.2 mmol/l.
21. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun C et al., Investigators for the Cholesterol and Recurrent Events Trial: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996, 335:1001-1009. The classic study that demonstrated that the benefits of lipid-lowering therapy may not be seen at LDL-cholesterol concentrations of less than 3.2mmol/l.
22. •].
23. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH, for the Harvard Atherosclerosis Reversibility Project (HARP) Group: Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet 1994, 344:1182-1186.
24. Tonkin AM, for the LIPID Study Group: Management of the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995, 76:107C-112C. A discussion of an ongoing large Antipodean study in relation to 4S [7].
25. Brown BG, Zhao X-Q, Poulin D, Albers JJ: Regression of atherosclerosis. Does it occur and does it have clinical meaning? Eur Heart J 1995, 16(Suppl E):2-5.
26. Mintz GS, Painter JA, Pichard AD, Kent KM, Satler LF, Popma JJ, Chuang YC, Bucher TA, Sokolowicz LE, Leon MB: Atherosclerosis in angiographically 'normal' coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 1995, 25:1479-1485. A clear demonstration that atherosclerosis is ubiquitous in apparently normal coronary artery reference segments. Intravascular ultrasound study is likely to be used more frequently in future trials.
27. Gould KL: Reversal of coronary atherosclerosis. Clinical promise as the basis of noninvasive management of coronary artery disease. Circulation 1994, 90:1558-1571.
28. Sorensen KE, Celermajor DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE: Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995, 74:247-253. Full validation of a noninvasive test for assessing endothelial dysfunction in peripheral conductance vessels. Despite excellent precision, the authors recommended individuals be studied on at least two occasions before and after intervention.
29. Thompson GR: Angiographic trials of lipid-lowering therapy: end of an era? Br Heart J 1995, 74:343-347.
30. ••].
31. ••] illustrating the potential therapeutic benefits of combined calcium antagonist and lipid-lowering therapy.
32. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lespérance J, for the CCAIT Study Group: Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Sub-study. Circulation 1995, 92:2404-2410. An important sub-analysis indicating that the benefits of statin therapy on progression of CAD extend to women.
33. MAAS Investigators: Effects of simvastatin of coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994, 344:633-638.
34. ••]. The authors also showed an early reduction in the rate of coronary events.
35. The Pravastatin Multinational Study Group for Cardiac Risk Patients: Effects of pravastatin in patients with serum total cholesterol levels from 5.2-7.8 mmol/l (200-300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993, 72:1031-1037.
36. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627. An important demonstration that pravastatin decreases the incidence of rejection with haemodynamic compromise and the incidence of coronary vasculopathy in cardiac transplants recipients.
37. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Buccuzzi SJ, Lespérance J, the CCAIT Study Group: Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994, 89:954-968.
38. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GBJ: Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995, 92:2419-2425. The authors pooled results of pravastatin trials that showed reduction in the risk of cardiovascular events in patients with atherosclerotic disease and mildly to moderately elevated cholesterol. Cardiovascular benefit was shown to be independent of age, sex, hypertension and previous myocardial infarction.
39. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347:849-853. The first angiographic demonstration that bezafibrate improves dyslipidaemia, lowers plasma fibrinogen and slows progression of coronary atherosclerosis in young patients with previous myocardial infarction. Angiographic changes were paralleled by significant reduction in coronary events.
40. Hodis HN, Mack WJ: Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol 1995, 6:209-214. A useful review of angiographic data showing that triglyceride-rich lipoproteins accelerate the progression of CAD.
41. Weintraub MS, Grosskopf I, Charach G, Mor R, Rubinstein A, Wollman Y, Judevices R, Iaina A: Bezafibrate therapy in patients with isolated low high-density lipoprotein cholesterol levels may have a beneficial effect in prevention of atherosclerosis. Metabolism 1995, 44:1401-1409.
42. Seiler C, Suter TM, Hess OM: Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol 1995, 26:1615-1622. The first demonstration of improvement in coronary vasomotor function with a fibrate.
43. Ishiwata S, Nakanishi S, Nishiyama S, Seki A: Prevention of restenosis by bezafibrate after successful coronary angioplasty. Coronary Artery Dis 1995, 6:883-889. An interesting study demonstrating the potential effect of bezafibrate in preventing restenosis in patients with hypertriglyceridaemia. The effect may in part be mediated by reduction in plasminogen activator 1-1 levels.
44. Bezafibrate Infarction Prevention (BIP) Study Group, Israel: Lipids and lipoproteins in symptomatic coronary heart disease. Circulation 1992, 86:839-848.
45. Modan B, Assman G, Bauer P, Kuller LH, Schoenberger J: Statement of the International Review and Advisory Board of the Bezafibrate Infarction Prevention Study after its meeting on May 31, 1995, in Charlottsville, Va. Circulation 1995, 92:1675.
46. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M: Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996, 77:31-36. The beneficial effect of n-3 fatty acids on the incidence of vein graft occlusion was demonstrated.
47. Sacks FM, Stone PH, Gibson CM, Silverman Dl, Rosner B, Pasternak RC, for the HARP Research Group: Controlled trial of fish oil for regression of human coronary atherosclerosis. J Am Coll Cardiol 1995, 25:1492-1498. No evidence was found by the Harvard Atherosclerosis Reversability Project group that fish oil supplements improved coronary atherosclerosis, but this might have been a result of the small sample size.
48. Yui Y, Kawai C, Hosoda S, and the Pravastatin Restenosis Trial Study Group: Pravastatin (mevalotin) restenosis trial after percutaneous transluminal coronary angioplasty: cholesterol reduction rate determines the restenosis rate. Ann N Y Acad Sci 1995, 748:208-216.
49. Austin GF: Lipids and vascular restenosis. Circulation 1992, 85:1613-1615.
50. Havranek EP: Is cholesterol lowering an alternative to revascularization in some patients with coronary artery disease? Arch Intern Med 1995, 155:670-675. A brief but important review outlining several null hypotheses for future trials comparing revascularization to cholesterol lowering therapy.
51. Hodis HN, Mack WJ, LaBree L, Cashin-Hemphill L, Sevanian A, Johnson R, Azen SP: Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995, 273:1849-1854. Sub-analysis from Cholesterol Lowering Atherosclerosis Study showing that reduction in progression of CAD is related to supplementary intake of vitamin E, but not vitamin C.
52. Anderson TJ, Meredith IT, Charbonneau F, Yeung AC, Frei B, Selwyn AP, Ganz P: Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996, 93:1647-1650. The first demonstration of direct association between susceptibility of LDL to oxidation and endothelial dysfunction in the coronary arteries.
53. Maher WMG, Brown BG, Marcovina SM, Hillyer LA, Zhao X-Q, Albers JJ: Effects of lowering elevated LDL-cholesterol on cardiovascular risk of lipoprotein(a). JAMA 1995, 274:1771-1774. Sub-analysis of fats showing that elevated Lp(a) is only atherogenic in the presence of an elevated serum concentration of LDL-cholesterol.
54. Thompson GR, Maher VMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P, Henderson A: Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995, 345:811-816. The first randomized angiographic trial in patients with familial hypercholesterolaemia demonstrating that the effects of colestipol plus simvastatin may match LDL apheresis plus simvastatin. The pathogenicity of Lp(a) is questioned.
55. Watts GF for the STARS Group: Nutritional, metabolic, and genetic determinants of the progression of coronary heart disease. J Cardiovasc Pharm 1995, 25(Suppl 4):S11-S19. A comprehensive assessment of the determinants of CAD from STARS. Candidate genes only explain a small proportion of variance of progression. LDL-cholesterol and dietary fat were the principal determinants of CAD.
56. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM: Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995, 73:209-215. A post-hoc analysis from STARS providing the first demonstration that a genetic polymorphism of stromelysin, a metaloproteinase that regulates collogen matrix, may be related to the progression of coronary atherosclerosis.
57. Watts GF, Mandalia S, Brunt JNH, Slavin BM, Coltart DJ, Lewis B: Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993, 42:1461-1467.
58. Mack WJ, Krauss RM, Hodis HN: Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996, 16:697-704.
59. Watts GF, Crook MA, Haq S, Mandalia S: Serum sialic acid as an indicator of change in coronary artery disease. Metabolism 1995, 44:1-2. A subsidiary analysis from STARS suggesting that increase in serum sialic acid levels may reflect progression of CAD.
60. Watts GF, Mandalia S, Slavin BM, Brunt JNH, Coltart DJ, Lewis B: Metabolic determinants of the course of coronary artery disease in men. Clin Chem 1994, 40:2240-2246.
61. Gould KL, Ornish D, Scherwitz L, Brown S, Edens RP, Hess MJ, Mullani N, Bolemey L, Dobbs F, Armstrong WT et al.: Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 1995, 274:894-901. Follow-up data from Lifestyle Heart Trial which showed significant improvement in myocardial perfusion after 5 years of intensive lifestyle risk factor modification.
62. Schlierf G, Schuler G, Hambrecht R, Niebauer J, Hauer K, Vogel G, Kubler W: Treatment of coronary heart disease by diet and exercise. J Cardiovasc Pharm 1995, 25(Suppl 4):S32-S34. The six-year follow-up data from the Heidelberg Exercise Diet Study showing disappointing compliance with dietary therapy.
63. Watts GF: Familial Hypercholesterolaemia Regression Study and its implications. Lancet 1995, 345:807-808.
64. Kroon AA, Aengevaeren WRM, van der Werf T, Uijen GJH, Reiber JHC, Bruschke AVG, Stalenhoef AFM: LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996, 93:1826-1835. Dutch trial confirming the findings of the Familial Atherosclerosis Treatment Study and showing an improvement in exercise electrocardiogram changes. The progression of CAD was positively correlated with in-trial cholesterol levels.
65. Dowell FJ, Hamilton CA, Lindop GBM, Reid JL: Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment. Arterioscler Thromb Vasc Biol 1995, 15:1152-1160.
66. Salonen JT, Salonen R: Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991, 11:1245-1249. Data supporting the use of carotid ultrasonography as a surrogate for CAD events.
67. Furberg CD, Pitt, B, Byington RP, Park J-S, McGovern MR, for the PLACI and PLACII Investigators: Reduction in coronary events during treatment with pravastatin. Am J Cardiol 1995, 76:60C-63C.
68. Walldius G, Erikson U, Olsson AG, Bergstrand L, Hådell K, Johansson J, Kaijser L, Lassvik C, Mölgaard J, Nilsson S, Schäfer-Elinder L, Stenport G, Holme I: The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994, 74:875-883.
69. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ and the MARS Group: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993, 119:969-976.
70. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B, for the Asymptomatic Carotid Artery Progression Study (ACAPS): Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994, 90:1679-1687.
71. Gotto AM: Effects of pravastatin in heart transplant recipients: implications of Kobashigawa et al. Curr Opin Lipidol 1995, 6:341-344.
72. Davis SF, Yeung AC, Meredith IT, Charbonneau F, Ganz P, Selwyn AP, Anderson TJ: Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year post transplant. Circulation 1996, 93:457-462. Further clinical evidence, based on the post-transplant model, showing that endothelial dysfunction in men antedates the development of coronary atherosclerosis.
73. Massey ZA, Keane WF, Kasiske BL: Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 1996, 347:102-103. A brief and informative review emphasizing that the cardiovascular benefits of statins may be mediated by reduction in isoprenoid metabolism.
74. Thompson GR, Hollyer J, Waters DD: Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995, 6:386-388. A meta-analysis of 11 angiographic trials suggesting that the percentage reduction in LDL-cholesterol may be a better target for treatment than an absolute level of LDL-cholesterol. Interpretation may be confounded by regression to the mean phenomenon.
75. Sacks FM, Gibson CM, Rosner B, Pasternak RC, Stone PH, and the Harvard Atherosclerosis Reversibility Project Research Group: The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypercholesterolemic therapy on coronary atherosclerosis in angiographic trials. Am J Cardiol 1995, 76:78C-85C. Pooled analysis of regression studies showing that greatest angiographic benefit is seen in relation to high pretreatment LDL-cholesterol concentrations. This would explain the 'paradoxical' relation between low on-treatment levels of LDL-cholesterol and progression of CAD. The findings could be confounded by regression to the mean effect.
76. Rossouw JE: Lipid-lowering interventions in angiographic trials. Am J Cardiol 1995, 76:86C-92C. A comprehensive meta-analysis of angiographic trials. The author emphasized that a minimum reduction in LDL may be needed to arrest progression of CAD.
77. Vandenbroucke JP, Westerdorp RGJ: Are the effects of cholesterol lowering drugs always equal? Lancet 1996, 347:1267-1268.
78. Watts GF, Burke V, Lewis B: Plasma low-density-lipoprotein cholesterol levels and progression of coronary atherosclerosis: a metaregression analysis of angiographic trials. Br J Cardiol 1997 (In press).
79. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Summary of the second report on the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993, 269:3015-3023.
80. European Atherosclerosis Society International Task Force for Prevention of Coronary Heart Disease: prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992, 2:113-156.
81. Brown BG, Stewart BF, Zhao X-Q, Hillger LA, Poulin D, Albers JJ: What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Am J Cardiol 1995, 76:93C-97C. Familial Atheroscerosis Treatment Study analysis showing that treating normocholesterolaemia may only be beneficial in patients with elevated plasma levels of apolipoproteinB.
82. Meyers DG. Relative survival benefits of risk factor modification. Am J Cardiol 1996, 77:298-299.
83. Grover SA, Coupal L, Xiao-Ping H: Identifying adults at increased risk of coronary disease. JAMA 1995, 274:801-806.
84. American College of Physicians. Guidelines for using serum cholesterol, high density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med 1996, 124:515-517. Provocative recommendations on cholesterol testing for prevention of CAD.
85. •].
86. Task Force on Risk reduction, American Heart Association: Cholesterol screening in asymptomatic adults. Circulation 1996, 93:1067-1068. The authors commented on ACP recommendations in relation to American Heart Association guidelines and supported the approach of the American Heart Association.
87. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, Levine DM: Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993, 328:313-318.
88. Anderson KM, Wilson PWF, Odell PW, Kanuel WB: An updated coronary risk profile: a statement for health professionals. Circulation 1991, 83:356-362.
89. Mann JI, Crooke M, Fear H, Hay DR, Jackson RI, Neutze JM, White HD: Guidelines for detection and management of dyslipidaemia. N Z Med J 1993, 106:133-141.
90. Pyörälä K, De Becker G, Graham I, Poole-Wilson P, Wood D: Prevention of coronary heart disease in clinical practice. Eur Heart J 1994, 15:1300-1331.
91. Chambless LE, Dobson AJ, Patterson CC, Raines B: On the use of a logistic risk score on predicting risk of coronary heart disease. Stats Med 1990, 9:385-396.
92. Haq IU, Jackson PR, Yeo WW, Ramsay LE: Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995, 346:1467-1471.
93. Jackson R, Beaglehole, R: Evidence-based management of dyslipidaemia. Lancet 1995, 346:1440-1442.
94. Lloyd JK: Cholesterol: should we screen all children or change the diet of all children. Acta Paediatr Scand 1991, Suppl 373:66-72.
95. Wilson PWF: Cholesterol screening. Once is not enough. Arch Intern Med 1995, 155:2146-2147.
96. Forrow L, Calkins DR, Allshouse K, Horowitz G, Delbanco TL: Evaluating cholesterol screening. Arch Intern Med 1995, 155:2177-2184.
97. Yusuf S, Anand S: Cost of prevention. The case of lipid lowering. Circulation 1996, 93:1774-1776. An interesting critique of the 4S trial [7] cost minimization analysis.
98. Oster G, Thompson D: Estimated effects of reducing dietary saturated fat intake on the incidence and costs of coronary heart disease in the United States. J Am Diet Assoc 1996, 96:127-131.
99. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyörälä K, Miettinen T, Haghfelt T, Faergeman O, Thorgeirsson G, Jönsson B, Schwartz JS, for the Scandinavial Simvastatin Survival Group: Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996, 93:1796-1802. Cost minimization analysis from 4S [7] showing that treating CAD patients with simvastatin reduces major costs of cardiovascular disease.
100. Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H, for the Scandinavian Simvastatin Survival Study Group: Eur Heart J 1996, 17:1001-1007. Further economic analysis from 4S data [7] showing that cholesterol lowering with simvastatin in post-MI and angina patients is cost-effective.
101. Davie AP, McMurray JJV: Cost-benefit analysis of lipid lowering therapy. Eur Heart J 1996, 17:974-975. Interesting perspective on 4S cost-benefit analysis [7] indicating that extrapolation of a cost-per-life year saved beyond end of trial may be inappropriate. Important comparisons are also made with trials of ACE inhibitors and antihypertensive agents.
102. ••].
103. Simes RJ, on behalf of the PPP and CTT Investigators: Prospective meta-analysis of cholesterol-lowering studies: The Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. Am J Cardiol 1995, 76:122C-126C. Prospectively planned meta-analyses of primary and secondary prevention trials which purport to avoid the pitfalls of meta-analytical procedures in earlier studies. The enormous database accrued will allow important questions to be answered regarding effects of cholesterol reduction and cause specific mortality and the effects of coronary mortality within relevant subgroups.
104. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE: The primary prevention of coronary heart disease in women. N Eng J Med 1995, 332:1758-1766. Compulsive reading. The authors review strategies for the primary prevention of coronary heart disease in women.
105. LaRosa JC, Applegate W, Crouse JR, Hunninghake DB, Gromm R, Knopp R, Eckfeldt JH, Davis CE, Gordon DJ: Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. Arch Intern Med 1994, 154:529-539.
106. Steinberg D: Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? Lancet 1995, 346:36-38. Essential reading to clarify the pathways for future clinical trials of antioxidants.
107. Naito M, Hayashi T, Iguchi A: New approaches to the prevention of atherosclerosis. Drugs 1995, 50:440-448. A focussed review highlighting the potential therapeutic role of oxidative modification of lipoproteins, treatment of hyperibrinogenaemia and homocysteinaemia, and improvement of nitric oxide physiology.
108. Feldman LJ, Isner JM: Gene therapy for the vulnerable plaque. J Am Coll Cardiol 1995, 26:826-835. A futuristic account of the role of gene therapy in the secondary prevention of coronary artery disease and atherosclerosis.